MAPT and Alzheimer disease: To our knowledge, this is the first study comparing parkinsonian syndromes (PSP and CBS) with and without AD biomarkers on measures of cognition, motor symptom burden, and neuroimaging findings of PET tau, white matter integrity, and volumes.